These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 16234526

  • 1. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM.
    J Clin Oncol; 2005 Oct 20; 23(30):7646-53. PubMed ID: 16234526
    [Abstract] [Full Text] [Related]

  • 2. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 1999 Jul 20; 5(7):1629-37. PubMed ID: 10430061
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS.
    J Clin Oncol; 2005 Oct 01; 23(28):7178-87. PubMed ID: 16192602
    [Abstract] [Full Text] [Related]

  • 4. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
    Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP.
    Clin Cancer Res; 2006 Mar 01; 12(5):1577-84. PubMed ID: 16533784
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
    Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A.
    Clin Cancer Res; 2007 Nov 15; 13(22 Pt 1):6712-8. PubMed ID: 18006772
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ.
    Clin Cancer Res; 1997 Jul 15; 3(7):1093-100. PubMed ID: 9815788
    [Abstract] [Full Text] [Related]

  • 7. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
    Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ.
    Clin Cancer Res; 2000 Aug 15; 6(8):3025-31. PubMed ID: 10955780
    [Abstract] [Full Text] [Related]

  • 8. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):909-15. PubMed ID: 20405511
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Friedman HS.
    Cancer; 2009 Jul 01; 115(13):2964-70. PubMed ID: 19402172
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S.
    Pediatr Blood Cancer; 2014 May 01; 61(5):833-9. PubMed ID: 24249672
    [Abstract] [Full Text] [Related]

  • 14. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ, Malkin MG, Kleber M, Abrey LE.
    Neuro Oncol; 2004 Jul 01; 6(3):247-52. PubMed ID: 15279717
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK.
    J Clin Oncol; 1999 Aug 01; 17(8):2604-13. PubMed ID: 10561328
    [Abstract] [Full Text] [Related]

  • 16. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Jones SF, Gian VG, Greco FA, Miranda FT, Shipley DL, Thompson DS, Hainsworth JD, Toomey MA, Willcutt NT, Burris HA.
    Oncology (Williston Park); 2003 May 01; 17(5 Suppl 5):41-5. PubMed ID: 12800606
    [Abstract] [Full Text] [Related]

  • 17. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, Krailo MD, Adamson PC, Children's Oncology Group Study.
    J Clin Oncol; 2007 Apr 20; 25(12):1512-8. PubMed ID: 17442993
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N.
    Chemotherapy; 2005 May 20; 51(2-3):154-61. PubMed ID: 15886476
    [Abstract] [Full Text] [Related]

  • 19. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE.
    Clin Cancer Res; 2001 Feb 20; 7(2):421-8. PubMed ID: 11234899
    [Abstract] [Full Text] [Related]

  • 20. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
    Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J.
    Oncotarget; 2015 Dec 15; 6(40):43127-34. PubMed ID: 26503473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.